First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy
about
Animal and human mucosal tissue models to study HIV biomedical interventions: can we predict success?Rectal pre-exposure prophylaxis (PrEP)Rectal transmission of transmitted/founder HIV-1 is efficiently prevented by topical 1% tenofovir in BLT humanized miceDevelopment of HIV-1 rectal-specific microbicides and colonic tissue evaluationCorrelation between compartmental tenofovir concentrations and an ex vivo rectal biopsy model of tissue infectibility in the RMP-02/MTN-006 phase 1 studyMucosal effects of tenofovir 1% gelRectal forceps biopsy procedure in cystic fibrosis: technical aspects and patients perspective for clinical trials feasibility.A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate.Use of human mucosal tissue to study HIV-1 pathogenesis and evaluate HIV-1 prevention modalities.Rectal microbicide development.A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1% gel (MTN-007).Rectal-specific microbicide applicator: evaluation and comparison with a vaginal applicator used rectally.Models for predicting effective HIV chemoprevention in womenT lymphocyte density and distribution in human colorectal mucosa, and inefficiency of current cell isolation protocols.A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study).The use of preexposure treatments for HIV prophylaxisDoes tenofovir gel or do other microbicide products affect detection of biomarkers of semen exposure in vitro?Assessing the potential of the Woman's Condom for vaginal drug deliveryUC781 microbicide gel retains anti-HIV activity in cervicovaginal lavage fluids collected following twice-daily vaginal applicationReformulated tenofovir gel for use as a dual compartment microbicide.Dose-response relationship between tissue concentrations of UC781 and explant infectibility with HIV type 1 in the RMP-01 rectal safety study.Nonreproducibility of "snap-frozen" rectal biopsies for later use in ex vivo explant infectibility studiesRMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarateDistinct Pharmacodynamic Activity of Rilpivirine in Ectocervical and Colonic Explant Tissue.Comprehensive assessment of HIV target cells in the distal human gut suggests increasing HIV susceptibility toward the anusDrug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment.Pharmacodynamic correlations using fresh and cryopreserved tissue following use of vaginal rings containing dapivirine and/or maraviroc in a randomized, placebo controlled trial.In Vivo Rectal Mucosal Barrier Function Imaging in a Large-Animal Model by Using Confocal Endomicroscopy: Implications for Injury Assessment and Use in HIV Prevention StudiesHIV-1 infection of female genital tract tissue for use in prevention studiesFuture prospects and perspectives on microbicides.Isoosmolar enemas demonstrate preferential gastrointestinal distribution, safety, and acceptability compared with hyperosmolar and hypoosmolar enemas as a potential delivery vehicle for rectal microbicidesHIV PrEP Trials: The Road to Success.The Promise of Antiretrovirals for HIV Prevention.Image-based noninvasive evaluation of colorectal mucosal injury in sheep after topical application of microbicides.HIV Infection is associated with compositional and functional shifts in the rectal mucosal microbiota.Methodological lessons from clinical trials and the future of microbicide research.The development of rectal microbicides for HIV prevention.An overview of antiretroviral pre-exposure prophylaxis of HIV infection."Like Holding an Umbrella Before It Rains": Acceptability of Future Rectal Microbicides Among Men Who Have Sex With Men in India-A Modified Technology Acceptance Model.Analytical Advances in the Ex Vivo Challenge Efficacy Assay.
P2860
Q26777022-77DB8107-E2BB-4DAA-8BE4-1665532FED66Q26829713-41838AA8-3ED0-4D4F-96C6-605B83FE407CQ28488527-D65292B2-43A5-48E3-84C4-6FC5821F150BQ28540761-3BF2CA3B-8D15-4DA7-8A27-842D5155DF41Q28544439-8F59DEB2-853C-4372-90D7-C143F6A22D50Q28545969-C03E62C4-614A-468C-8F4E-1B090691332FQ30540580-45CCEA48-45CC-4A34-B596-CBE4001374F4Q34414539-7F7846D9-24E9-4693-80D6-4D9D57D5C6DDQ34566597-05C9E2E0-188B-4713-BEDD-DB2B6E902F62Q34575590-77CC33ED-C2EA-4045-82A9-B3948A53214DQ34661892-73D8BBCC-BA90-4B14-A431-83A8E53360C3Q35061678-66E63CB8-4137-480A-95DF-30389BD05C0FQ35102285-89C0393F-488C-492D-B1DA-6C0218F1DD2DQ35344900-1D560B0D-072E-4B8F-9477-08AE51DDE819Q35571216-107ECE70-BC5F-4634-8A38-1958A463EF98Q35760180-BD1F7952-A4CA-4753-AFEC-0FED445AD0F4Q35990151-7D07BC48-E9CF-42FA-905E-3C223FB5E636Q36039442-508F800F-90CF-4F03-8E80-DACB6C1C64E0Q36086344-97B2D685-6B36-472D-BA40-55E5C8386DB7Q36159765-7EB50055-3BEC-4EF9-98F5-EC260E52B9DDQ36358774-EF10A858-ABDF-496A-93F4-E20966C8CAD0Q36359000-EDE59E68-17C6-4C8E-BF72-70E444E98EEEQ36359092-3A492062-B1F0-4402-8693-5967D2D933EDQ36888077-459575B4-D160-40A6-851C-AFF957E38722Q36930438-09F097B2-E136-46EE-A796-8E678B4BCBDCQ36934918-DAE94340-3858-48BB-B2E3-BA061E5E4AEEQ37116845-1A62B20B-76AA-4F88-96F2-4CD8E5234D6EQ37120136-12559568-E10A-4880-9249-C331005B7A7AQ37141860-9D5BDD35-A8D7-4AC4-AC01-EE5B2209F4B2Q37244916-C1BC7804-57D7-4DBD-93B1-DE18FAA534BDQ37259803-06B46944-B16C-4F42-AF99-0D281D7DC306Q37438644-E1063D8D-5E5D-4CE8-A432-AE8876AD37E5Q37511883-7CA1AD04-4460-4746-80CF-909571BDEBC7Q37514873-4E863ADF-B446-4C74-8180-34E7FBFE3D0EQ37677371-A9C65F7B-23B3-4465-A05A-C3C707B5F347Q38062882-706D98D9-39E1-4A8D-B22D-AF400D31C1A0Q38165222-EA66E255-CEE7-4C60-82EF-38C95B1B9BC1Q38196410-60EE6C86-8971-4722-BE73-038172DED075Q38662018-82A1FE04-D282-49A6-B6BE-D47EA1AB45B8Q39189916-4A3F4071-0E73-4D2B-87DF-097727BD7847
P2860
First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
First phase 1 double-blind, pl ...... ovel index of ex vivo efficacy
@ast
First phase 1 double-blind, pl ...... ovel index of ex vivo efficacy
@en
First phase 1 double-blind, pl ...... ovel index of ex vivo efficacy
@en-gb
First phase 1 double-blind, pl ...... ovel index of ex vivo efficacy
@nl
type
label
First phase 1 double-blind, pl ...... ovel index of ex vivo efficacy
@ast
First phase 1 double-blind, pl ...... ovel index of ex vivo efficacy
@en
First phase 1 double-blind, pl ...... ovel index of ex vivo efficacy
@en-gb
First phase 1 double-blind, pl ...... ovel index of ex vivo efficacy
@nl
altLabel
First Phase 1 Double-Blind, Pl ...... ovel Index of Ex Vivo Efficacy
@en
prefLabel
First phase 1 double-blind, pl ...... ovel index of ex vivo efficacy
@ast
First phase 1 double-blind, pl ...... ovel index of ex vivo efficacy
@en
First phase 1 double-blind, pl ...... ovel index of ex vivo efficacy
@en-gb
First phase 1 double-blind, pl ...... ovel index of ex vivo efficacy
@nl
P2093
P2860
P3181
P1433
P1476
First phase 1 double-blind, pl ...... ovel index of ex vivo efficacy
@en
P2093
Alex Carballo-Diéguez
Christine Mauck
Elena Khanukhova
Galen Cortina
Henry Gabelnick
Ian McGowan
John Boscardin
Julie Elliott
Karen Tanner
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0023243
P407
P577
2011-01-01T00:00:00Z